Stonegate Capital Partners has updated its coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The company's lead program, NEO212, is a next-generation version of temozolomide (TMZ), the standard-of-care chemotherapy used in most brain cancer patients. It is designed to address key limitations of current treatment including BBB penetration and MGMT-driven resistance.
Beyond its lead programs, NeOnc's platform approach combines intranasal and oral drug delivery technologies designed to improve CNS drug penetration, supporting additional opportunities across multiple brain tumor indications. NTHI recently led a successful PIPE offering, adding a gross $16.0M to the company's balance sheet.
Key takeaways from the update include NEO212's clinical momentum: Phase 1 dose escalation in recurrent glioblastoma (GBM) has completed with a Recommended Phase 2 Dose of 610 mg established and early signs of disease control observed, positioning the program to advance into Phase 2 efficacy evaluation. NEO100, an intranasal therapy, is a non-invasive drug delivery approach targeting recurrent GBM, with Phase 2 data showing radiographic responses and improved progression-free survival versus historical salvage benchmarks.
For more details, view the full announcement here.
